← brief for 2026-08-11 · Slowing decline

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Trial No results yet Not peer reviewed

Key takeaways

This phase 3 trial tests a drug called elecoglipron against a placebo (a dummy treatment) in adults who have type 2 diabetes and reduced kidney function. Everyone also takes the standard kidney and diabetes drug dapagliflozin. The study is beginning, so there are no results yet.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-04
https://clinicaltrials.gov/study/NCT07662135